Literature DB >> 29864500

Review and mapping of carbapenem-resistant Enterobacteriaceae in Africa: Using diverse data to inform surveillance gaps.

Elizabeth A Mitgang1, David M Hartley2, Marissa D Malchione3, Michala Koch3, Jesse L Goodman4.   

Abstract

Carbapenem-resistant Enterobacteriaceae (CRE) are among the most difficult to treat emerging multidrug-resistant organisms. Major limitations exist in surveillance needed to address CRE, particularly in areas with inadequate resources. We utilised optimised strategies to search for data on carbapenem susceptibility of Klebsiella spp. and Escherichia coli from the World Health Organization (WHO) Africa Region. Core data elements were extracted for meta-analysis and mapping. Despite sparse data in existing reviews, 180 documents including 314 reports on susceptibility of E. coli and/or Klebsiella were located, providing information on 31 (66%) of 47 nations. Carbapenem-resistant E. coli or Klebsiella were identified in 22 (71%) of these 31 countries. Crude resistance proportions were estimated for nations with >100 representative isolates. Median resistance among E. coli was <1% in 11 (61%) of 18 nations meeting criteria, 1-5% in 6 nations (33%) and >5% in 1 nation (6%). For Klebsiella spp., corresponding figures were <1% in 10 (67%) of 15 nations, 1-5% in 3 nations (20%) and >5% in 2 nations (13%). Comprehensive, customised search strategies with analysis and mapping of defined data elements provide an enhanced view of carbapenem-resistant E. coli and Klebsiella in Africa. These CRE are widely distributed and are generally present at low to moderate levels. Whilst use of diverse and largely clinically derived data has limitations and cannot substitute for surveillance, it can enhance situational awareness. The approaches utilised can support improved risk understanding and prioritisation and may be applied to other micro-organisms and areas where surveillance remains inadequate.
Copyright © 2018 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.

Entities:  

Keywords:  Africa; Antimicrobial resistance; Carbapenem; Enterobacteriaceae; Mapping; Surveillance

Mesh:

Substances:

Year:  2018        PMID: 29864500     DOI: 10.1016/j.ijantimicag.2018.05.019

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  5 in total

1.  Spread of NDM-5 and OXA-181 Carbapenemase-Producing Escherichia coli in Chad.

Authors:  Yann Dumont; Fabrice Compain; Sylvain Godreuil; Oumar Ouchar Mahamat; Manon Lounnas; Mallorie Hide; Abelsalam Tidjani; Julio Benavides; Abibatou Diack; Calèbe Somasse; Kadidja Gamougam; Christian Carrière; Dominique Decré; Anne-Laure Bañuls; Hélène Jean-Pierre
Journal:  Antimicrob Agents Chemother       Date:  2019-10-22       Impact factor: 5.191

2.  Epidemiology of Carbapenem Resistance Determinants Identified in Meropenem-Nonsusceptible Enterobacterales Collected as Part of a Global Surveillance Program, 2012 to 2017.

Authors:  Krystyna M Kazmierczak; James A Karlowsky; Boudewijn L M de Jonge; Gregory G Stone; Daniel F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2021-06-17       Impact factor: 5.191

3.  Epidemiology of Carbapenem-resistant Enterobacteriaceae in Egyptian intensive care units using National Healthcare-associated Infections Surveillance Data, 2011-2017.

Authors:  Sara Kotb; Meghan Lyman; Ghada Ismail; Mohammad Abd El Fattah; Samia A Girgis; Ahmed Etman; Soad Hafez; Jehan El-Kholy; Maysaa El Sayed Zaki; Hebat-Allah G Rashed; Ghada M Khalil; Omar Sayyouh; Maha Talaat
Journal:  Antimicrob Resist Infect Control       Date:  2020-01-03       Impact factor: 4.887

Review 4.  Carbapenem-Resistant Enterobacteriaceae-Implications for Treating Acute Leukemias, a Subgroup of Hematological Malignancies.

Authors:  Kristin Ølfarnes Storhaug; Dag Harald Skutlaberg; Bent Are Hansen; Håkon Reikvam; Øystein Wendelbo
Journal:  Antibiotics (Basel)       Date:  2021-03-19

5.  Detection of diverse carbapenem and multidrug resistance genes and high-risk strain types among carbapenem non-susceptible clinical isolates of target gram-negative bacteria in Kenya.

Authors:  Lillian Musila; Cecilia Kyany'a; Rosslyn Maybank; Jason Stam; Valerie Oundo; Willie Sang
Journal:  PLoS One       Date:  2021-02-22       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.